ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.

Emerson A Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.